ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

emicizumab

Its studies are mostly in Hemophilia A, led by 2 companies.

Drug pageEmicizumab: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 20, 201713 company-led studies, 4 open or runningNext primary completion: Nov 19, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche123 open or runningphase 4since Nov 20, 2017Dec 2, 2015Nov 19, 2026phase 4 · NCT05181618
Sanofiits history only11 open or runningphase 4since Nov 17, 2023Nov 17, 2023May 28, 2028phase 4 · NCT06145373

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named emicizumabINNProposed as its International Nonproprietary Name in WHO's List 113
  2. Dec 2, 2015First study: phase 3 study in Hemophilia AFirst studyNCT02622321 · 113 enrolled · United States, Australia, Costa Rica and more
  3. Jun 7, 2016Phase 3 study in Hemophilia ANCT02795767 · 88 enrolled · United States, Costa Rica, France and more
  4. Jul 26, 2016Phase 3 study in Hemophilia ANCT02847637 · 152 enrolled · United States, Australia, Costa Rica and more
  5. Dec 21, 2016Phase 3 study in Hemophilia ANCT03020160 · 48 enrolled · United States, Australia, Belgium and more
  6. Jun 15, 2017Phase 3 study in Hemophilia ANCT03191799 · 195 enrolled · Australia, Belgium, Brazil and more
  7. Oct 17, 2017Phase 3 study in Hemophilia ANCT03315455 · 85 enrolled · China, Hong Kong, Malaysia and more
  8. Nov 20, 2017Phase 4 study in Hemophilia ANCT03361137 · 14 enrolled · United States
  9. Dec 13, 2017Phase 1 study in Hemophilia ANCT03380780 · 16 enrolled · China
  10. Nov 7, 2019Phase 3 study in Hemophilia ANCT04158648 · 73 enrolled · United States, Belgium, Canada and more
  11. Jun 11, 2020Phase 3 study in Hemophilia ANCT04431726 · 55 enrolled · United States, Australia, Austria and more
  12. Dec 6, 2021Phase 4 study in Hemophilia ANCT05181618 · 136 enrolled · United States, Brazil, Canada and more
  13. May 22, 2025Phase 3 study in von Willebrand Disease, Type 3NCT06998524 · 75 planned · United States, Belgium, Canada and more
  14. Nov 16, 2026Primary completion moved from 2027-04-30 to 2027-10-06Date moved laterphase 3 · +5 months · NCT06998524

Ahead

  1. Nov 19, 2026Primary completion: phase 4 study in Hemophilia ANCT05181618
  2. Oct 6, 2027Primary completion: phase 3 study in von Willebrand Disease, Type 3NCT06998524

TargetBeta

F10 →F9 →read by rule
“Coagulation factor IX and X other”ChEMBL 37, by rule

Studies

All 12 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06998524von Willebrand Disease, Type 3 · United States, Belgium, Canada and more3RecruitingOct 6, 202775
NCT05181618Hemophilia A · United States, Brazil, Canada and more4Active, not recruitingNov 19, 2026136
NCT04431726Hemophilia A · United States, Australia, Austria and more3Active, not recruitingMay 22, 202355
NCT04158648Hemophilia A · United States, Belgium, Canada and more3CompletedOct 30, 202173
NCT03380780Hemophilia A · China1CompletedSep 18, 201816
NCT03361137Hemophilia A · United States4TerminatedMar 13, 202014
NCT03315455Hemophilia A · China, Hong Kong, Malaysia and more3CompletedAug 3, 202285
NCT03191799Hemophilia A · Australia, Belgium, Brazil and more3CompletedNov 19, 2020195
NCT03020160Hemophilia A · United States, Australia, Belgium and more3CompletedDec 15, 201748
NCT02847637Hemophilia A · United States, Australia, Costa Rica and more3CompletedSep 15, 2017152
NCT02795767Hemophilia A · United States, Costa Rica, France and more3CompletedApr 30, 201888
NCT02622321Hemophilia A · United States, Australia, Costa Rica and more3CompletedOct 25, 2016113

How it is read

Names in the registry

  • “Emicizumab”, 13 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.